Last year, the American Cancer Society predicted that in 2024, the US would reach two million annual new cancer cases for the first time in history. This number is staggering and signifies that cancer is truly a disease that impacts many lives each day.
While not all of these cases result in the grueling treatment associated with chemotherapy and radiation, many of those diagnosed will face the difficult road to recovery. Patients in chemotherapy experience a range of symptoms, from
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Novo Nordisk Amps Up Drug Discovery with Gefion AI Supercomputer
What You Should Know:
-DCAI today announced that Novo Nordisk has become a customer of the Gefion AI supercomputer.
- Through this agreement, Novo Nordisk will gain access to Gefion's unparalleled computational capabilities to process vast datasets, with a goal of transforming drug discovery and development as well as driving healthcare innovation.
AI-Powered Supercomputing Alliance to Advance Drug Discovery at Scale
In a landmark multiyear agreement, Novo Nordisk and Gefion have
Read More
Lieber Institute and AWS Collaborate to Optimize Drug Discovery for Brain Disorders
What You Should Know:
- The Lieber Institute for Brain Development (LIBD) is expanding its technology capabilities on Amazon Web Services (AWS), migrating its IT infrastructure to fully utilize AWS generative AI and compute services to advance its research.
- A recipient of the 2024 AWS IMAGINE Grant, the Institute plans to develop a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as
Read More
From Raw Records to Real-Time Insights: Climbing Pharma’s Real-World Data Maturity Curve
Real-world data (RWD) has become the pharmaceutical industry's most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.
We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and
Read More
Nicoya Lifesciences Acquires Applied Photophysics to Accelerate Drug Discovery
What You Should Know:
- Nicoya Lifesciences, Inc., a leading provider of advanced biologics characterization tools for drug discovery and development, today announced its acquisition of Applied Photophysics, a UK-based provider of biophysical characterization instrumentation.
- Applied Photophysics, bringing a 50-year history of delivering established analytical methods and reliable instrumentation, will now operate as part of Nicoya.
Nicoya Expands Biopharmaceutical Analytics
Read More
Mission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution
What You Should Know:
- Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells.
- The assay, which can be leveraged for Phase 2 or 3 trials to home in on patients most likely to
Read More
Oxford Cancer Biomarkers and Mira Precision Health Partner to Advance ToxNav® Cancer Test
What You Should Know:
- Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc.
- This collaboration aims to advance OCB's proprietary ToxNav® test in the United States, a revolutionary precision oncology tool designed to identify patients at high risk of severe toxicity from common chemotherapy treatments.
- Mira Precision Health, headquartered at the Mason 5155 BioHub in
Read More
The NP/PA Factor: Why Advanced Practice Providers Are Essential for Life Sciences in 2025
For decades, life sciences companies have centered their marketing efforts on physicians, assuming they hold the greatest influence over prescribing and treatment decisions. However, the healthcare landscape has shifted dramatically. Nurse practitioners (NPs) and physician assistants/associates (PAs) are not just supporting players, they are primary prescribers shaping patient care across nearly every therapeutic area.
This shift is finally being recognized across the industry. According to
Read More
Kyron.bio Secures $6.2M to Optimize Biologic Drug Development with Precision Glycan Engineering
What You Should Know:
- Biotechnology company kyron.bio announced the successful closing of a $6.2M (€5.5M) seed funding round aimed at solving critical challenges in biologic drug development, specifically varying efficacy and the dangers of side effects.
- The round was led by HCVC, with participation from Verve Ventures, Entrepreneurs First, Saras Capital, and numerous reputable angel investors.
- The funds will be used to accelerate the development of kyron.bio’s proprietary
Read More
Brooklyn Health Secures $6.5M to Expand AI-Powered Precision for Clinical Trial Endpoints
What You Should Know:
- Brooklyn Health, a neuroscience technology company focused on objective measurement of mental health announced it has secured $6.5M in seed funding led by HealthX, with participation from Metrodora Ventures, Story Ventures, RiverPark Ventures, Laconia Capital, Everywhere Ventures, Hypothesis Studio, Blue Falcon Capital, and others.
- The funding coincides with the company's debut of its new electronic clinical outcome assessment (eCOA) solution, Willis. Willis
Read More
